Harmol induces autophagy and subsequent apoptosis in U251MG human glioma cells through the downregulation of survivin

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1333-1342

  Abe, Akihisa ^a   Kokuba, Hiroko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Autophagy; Harmol; Mammalian target of rapamycin pathway; Survivin

Indexed keywords

3 METHYLADENINE; CHLOROQUINE; DIMETHYL SULFOXIDE; HARMOL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE; SMALL INTERFERING RNA; SURVIVIN;

APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; MEMBRANE FORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELLS AND CELL LINES; U251MG CELL;

APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HARMINE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84874698330     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2242     Document Type: Article

References (75)

1. DeAngelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001.
2. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006.
3. Kanzawa T, Kondo Y, Ito H, Kondo S and Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63: 2103-2108, 2003.
4. Fadeel B, Orrenius S and Zhivotovsky B: Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 266: 699-717, 1999.
5. Clarke PG: Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol 181: 195-213, 1990.
6. Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237, 2005.
7. Klionsky DJ and Emr SD: Autophagy as a regulated pathway of cellular degradation. Science 290: 1717-1721, 2000.
8. Levine B and Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463-477, 2004.
9. Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science 306: 990-995, 2004.
10. Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906, 2004.
11. Debnath J, Baehrecke EH and Kroemer G: Does autophagy contribute to cell death? Autophagy 1: 66-74, 2005.
12. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
13. Ogier-Denis E and Codogno P: Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 1603: 113-128, 2003.
14. Corcelle E, Nebout M, Bekri S, et al: Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity. Cancer Res 66: 6861-6870, 2006.
15. Otsuka H and Moscowitz M: Differences in the rates of protein degradation in untransformed and transformed cell lines. Exp Cell Res 112: 127-135, 1978.
16. Kirkegaad K, Taylor MP and Jacson WT: Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol 2: 301-314, 2004.
17. List PH and Hörhammer L: Hager's Hand book for Pharmaceutical Practice. Springer-Verlag, Berlin, 1970.
18. Naranjo C: Psychotropic properties of the harmala alkaloids. In: Ethnopharmacological Search for Psychoactive Drugs. Efron DH, Holmestedt B and Kline NS (eds). U.S. Public Health Service, New York, pp385-392, 1967.
19. Nadikarni KM: Indian Material Medica. Vol. 1. Popular Pakistan Limited, Bombay, pp927-929, 1976.
20. Dymock W, Warden CJ and Hooper D: Pharmacopia Indica. Vol. 1. Harmad National Foundation of Pakistan, pp252-253, 1976.
21. Khan SI, Abourashed EA, Khan IA and Walker LA: Transport of human alkaloids across Caco-2 cell monolayers. Chem Pharm Bull 52: 394-397, 2004.
22. Airaksinen MM and Kari I: ß-carbolines, psychoactive compounds in the mammalian body. Part I: occurrence, origin and metabolism. Med Biol 59: 21-34, 1981.
23. Beck O and Faull KF: Concentrations of the enantiomers of 5-hydroxymethylptoline in mammalian urine: Implications for in vivo biosynthesis. Biochem Pharmacol 65: 97-106, 1986.
24. Sobhani AM, Ebrahimi SA and Mahmoudian MJ: An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seed extract and its beta-carboline alkaloids. Pharm Pharm Sci 5: 19-23, 2002.
25. Lamchouri F, Setaff A, Cherrah Y, et al: Antitumor principles from Peganum harmala seeds. Therapie 54: 753-758, 1999.
26. Kuo PC, Shi LS, Damu AG, et al: Cytotoxic and antimalarial beta-carboline alkaloids from the roots of Eurycoma longifolia. J Nat Prod 66: 1324-1327, 2003.
27. Abe A and Yamada H: Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs 20: 373-381, 2009.
28. Abe A, Yamada H, Moriya S and Miyazawa K: The ß-carboline alkaloid harmol induces cell death via autophagy but not apoptosis in human non-small cell lung cancer A549 cells. Biol Pharm Bull 34: 1264-1272, 2011.
29. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539, 1998.
30. Biederbick A, Kern HF and Elsässer HP: Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 66: 3-14, 1995.
31. Kabeya Y, Mizusima N, Ueno T, et al: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728, 2000.
32. Seglen PO and Gordon PB: 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepa¬tocytes. Proc Natl Acad Sci USA 79: 1889-1892, 1982.
33. Kawai A, Uchiyama H, Takano S, Nakamura S and Ohkuma S: Autophagosome-lysosome fusion depends on the pH in acidic compartments in CHO cells. Autophagy 3: 154-157, 2007.
34. Rubinsztein DC, Gestwicki JE, Murphy LO and Klionsky DJ: Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6: 304-312, 2007.
35. Fu L, Kim AY, Wang X, et al: Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69: 8967-8976, 2009.
36. Viola G, Bortolozzi R, Hamel E, et al: MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol 8: 16-26, 2012.
37. Hung JY, Hsu YL, Li CT, et al: 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. J Agric Food Chem 57: 9809-9816, 2009.
38. Takeuchi H, Kanzawa T, Kondo Y and Kondo S: Inhibition of platelet-derived growth factor signaling induces autophagy in malignant glioma cells. Br J Cancer 90: 1069-1075, 2004.
39. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
40. Gross A, Yin XM, Wang K, et al: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163, 1999.
41. Zha J, Weiler S, Oh KJ, Wei MC and Korsmeyer SJ: Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290: 1761-1765, 2000.
42. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E and Pommier Y: Activation of the Fas pathway indepen¬dently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 20: 1852 1859, 2001.
43. Deveraux Q and Reed JC: IAP family proteins: suppressors of apoptosis. Genes Dev 13: 239-252, 1999.
44. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
45. Monzo M, Rosell R, Felip E, et al: A novel anti-apoptosis gene: re-expression of surviving messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999.
46. Adida C, Haioun C, Gaulard P, et al: Prognostic significance of surviving expression in diffuse large B-cell lymphomas. Blood 96: 1921-1925, 2000.
47. Kato J, Kuwabara Y, Mitani M, et al: Expression of surviving in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92-95, 2001.
48. Altieli DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
49. Levine B and Yuan J: Autophagy in cell death: an innocent convict? J Clin Invest 115: 2679-2688, 2005.
50. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
51. Petiot A, Pattingre S, Arico S, Meley D and Codongo P: Diversity of signaling controls of macroautophagy in mammalian cells. Cell Struct Funct 27: 431-441, 2002.
52. Pattingre S, Bauvy C and Codongo P: Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells. J Biol Chem 278: 16667-16674, 2003.
53. Meley D, Bauvy C, Houben-Weerts JH, et al: AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 281: 34870-34879, 2006.
54. Herrero-Martín G, Høyer-Hansen M, García- García C, et al: TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 28: 677-685, 2009.
55. Djavaheri-Mergny M, Maiuri MC and Kroemer G: Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 29: 1717-1719, 2010.
56. Zhou F, Yang Y and Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 278: 403-413, 2011.
57. Lin CC, Lee CW, Chu TH, et al: Transactivation of Src, PDGF receptor, and Akt is involved in IL-1beta-induced ICAM-1 expression in A549 cells. J Cell Physiol 211: 771-780, 2007.
58. Russo P, Catassi A, Cesario A and Servent D: Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. Curr Med Chem 13: 3493-3512, 2006.
59. Akca H, Tani M, Hishida T, Matsumoto S and Yokota J: Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 54: 25-33, 2006.
60. Kishimoto H, Ohteki T, Yajima N, et al: The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood 109: 3316-3324, 2007.
61. Takeuchi H, Kondo Y, Fujiwara K, et al: Synergistic augmen¬tation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65: 3336-3346, 2005.
62. Rommelspacher H, Nanz C, Borbe HO, Fehske KJ, Müller WE and Wollert U: 1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding. Naunyn Schmiedebergs Arch Pharmacol 314: 97-100, 1980.
63. Ho BT: Pharmacological and biochemical studies with beta-carboline analogs. Curr Dev Psychopharmacol 4: 151-177, 1977.
64. Poirier LJ, Sourkes TL, Bouvier G, Boucher R and Carabin S: Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain 89: 37-52, 1966.
65. Bruinvels J and Sourkes TL: Influence of drugs on the temperature-lowering effect of harmaline. Eur J Pharmacol 4: 31-39, 1969.
66. Zetler G, Back G and Iven H: Pharmacokinetics in the rat of the hallucinogenic alkaloids harmine and harmaline. Naunyn Shemiedebergs Arch Pharmacol 285: 273-292, 1974.
67. Grella B, Dukat M, Young R, et al: Investigation of halluci¬nogenic and related beta-carbolines. Drug Alcohol Depend 50: 99-107, 1998.
68. Udenfriend S, Wiycop B, Redfield BG and Weissbach H: Studies with reversible inhibitors of monoamine oxidase: harmaline and related compounds. Biochem Pharmacol 1: 160-165, 1958.
69. McIsaac WM and Estevez V: Structure-action relationship of beta-carbolines as monoamine oxidase inhibitors. Biochem Pharmacol 15: 1625-1627, 1966.
70. Loew GH, Nienow J, Lawson JA, Toll L and Uyeno ET: Theoretical structure-activity studies of beta-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol Pharmacol 28: 17-31, 1985.
71. Kim H, Sablin SO and Ramsay RR: Inhibition of monoamine oxidase A by ß-carboline derivatives. Arch Biochem Biophys 337: 137-142, 1997.
72. Gunn JA: Relations between chemical constitution, pharmaco¬logical actions, and therapeutic uses in the harmine group of alkaloids. Arch Int Pharmacodyn 50: 379-396, 1935.
73. Zetler G, Singbart G and Schlosser L: Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology 7: 237-248, 1972.
74. Yu AM, Idle JR, Krausz KW, Küpfer A and Gonzalez FJ. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305: 315-322, 2003.
75. Slotkin TA, DiStefano V and Au WY: Blood levels and urinary excretion of harmine and its metabolites in man and rats. J Pharmacol Exp Ther 173: 26-30, 1970.